Home › Frailty › NCT05018767

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of Aging Frailty
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur

About the study

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Aging Frailty

What is being tested

• cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 86 · Started: Jan 22, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05018767

Locations in the U.S.

Conditions

• Frailty

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.